Duality of Antidepressants and Neuroprotectants

[1]  S. Russo,et al.  Pathogenesis of depression: Insights from human and rodent studies , 2016, Neuroscience.

[2]  F. Najafi,et al.  Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair , 2015, Neuropharmacology.

[3]  D. Bredt,et al.  Translating depression biomarkers for improved targeted therapies , 2015, Neuroscience & Biobehavioral Reviews.

[4]  Mary S. Lopez,et al.  Resveratrol neuroprotection in stroke and traumatic CNS injury , 2015, Neurochemistry International.

[5]  J. Krakauer,et al.  Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model , 2015, Stroke.

[6]  J. Suckling,et al.  BDNF Val66Met polymorphism in patterns of neural activation in individuals with MDD and healthy controls. , 2015, Journal of affective disorders.

[7]  E. R. Kasala,et al.  Resveratrol ameliorates depressive-like behavior in repeated corticosterone-induced depression in mice , 2015, Steroids.

[8]  Y. Mineur,et al.  Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states , 2015, Neuropharmacology.

[9]  Xuan Sun,et al.  Fluoxetine enhanced neurogenesis is not translated to functional outcome in stroke rats , 2015, Neuroscience Letters.

[10]  A. Corbett,et al.  Increasing neurogenesis with fluoxetine, simvastatin and ascorbic Acid leads to functional recovery in ischemic stroke. , 2015, Recent patents on drug delivery & formulation.

[11]  V. Echeverria,et al.  Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder. , 2015, Current pharmaceutical design.

[12]  Xin Wang,et al.  Plant-derived neuroprotective agents in Parkinson's disease. , 2015, American journal of translational research.

[13]  B. Baune,et al.  An Act of Balance Between Adaptive and Maladaptive Immunity in Depression: a Role for T Lymphocytes , 2015, Journal of Neuroimmune Pharmacology.

[14]  P. Hardy,et al.  BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. , 2015, Pharmacogenomics.

[15]  L. Pei,et al.  Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study , 2015, Journal of clinical psychopharmacology.

[16]  Shafiqur Rahman.  Targeting brain nicotinic acetylcholine receptors to treat major depression and co-morbid alcohol or nicotine addiction. , 2015, CNS and Neurological Disorders - Drug Targets.

[17]  Katsunori Kobayashi,et al.  Role of the 5-HT4 receptor in chronic fluoxetine treatment-induced neurogenic activity and granule cell dematuration in the dentate gyrus , 2015, Molecular Brain.

[18]  F. Tarazi,et al.  Gene–Environment Interaction in Major Depression: Focus on Experience-Dependent Biological Systems , 2015, Front. Psychiatry.

[19]  Hai-tao Zhu,et al.  Curcumin improves neural function after spinal cord injury by the joint inhibition of the intracellular and extracellular components of glial scar. , 2015, The Journal of surgical research.

[20]  T. Celikel,et al.  The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: Central mediators of pathophysiology and antidepressant activity? , 2015, Neuroscience & Biobehavioral Reviews.

[21]  John H Krystal,et al.  Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants , 2015, Annals of the New York Academy of Sciences.

[22]  Allison C. Nugent,et al.  Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review , 2015, Therapeutic advances in chronic disease.

[23]  J. Haase,et al.  Integrating the monoamine, neurotrophin and cytokine hypotheses of depression--a central role for the serotonin transporter? , 2015, Pharmacology & therapeutics.

[24]  Ronald C Kessler,et al.  The economic burden of adults with major depressive disorder in the United States (2005 and 2010). , 2015, The Journal of clinical psychiatry.

[25]  P. Masand,et al.  Curcumin as a putative antidepressant , 2015, Expert review of neurotherapeutics.

[26]  E. Kavalali,et al.  How does ketamine elicit a rapid antidepressant response? , 2015, Current opinion in pharmacology.

[27]  Y. Panahi,et al.  Investigation of the Efficacy of Adjunctive Therapy with Bioavailability‐Boosted Curcuminoids in Major Depressive Disorder , 2015, Phytotherapy research : PTR.

[28]  S. Appenzeller,et al.  The importance of cytokines and autoantibodies in depression. , 2015, Autoimmunity reviews.

[29]  U. Bommhardt,et al.  NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells , 2014, Cell Communication and Signaling.

[30]  K. Tansey,et al.  An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. , 2014, The American journal of psychiatry.

[31]  B. Koch,et al.  Molecular and genetic basis of depression , 2014, Journal of Genetics.

[32]  L. Hurley,et al.  Relevance of the Anti-Inflammatory Properties of Curcumin in Neurodegenerative Diseases and Depression , 2014, Molecules.

[33]  Lin Yuan,et al.  The effects of curcumin on depressive-like behavior in mice after lipopolysaccharide administration , 2014, Behavioural Brain Research.

[34]  M. Kakinohana.  Protective effects of anesthetics on the spinal cord. , 2014, Current pharmaceutical design.

[35]  A. Araszkiewicz,et al.  The role of the neuroendocrine and immune systems in the pathogenesis of depression , 2014, Pharmacological reports : PR.

[36]  B. Aggarwal,et al.  Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. , 2014, Archives of biochemistry and biophysics.

[37]  M. Quik,et al.  Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. , 2014, Pharmacology & therapeutics.

[38]  M. Maes,et al.  Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. , 2014, Journal of affective disorders.

[39]  G. D. Griffin,et al.  Neuroprotective effects of resveratrol in Alzheimer disease pathology , 2014, Front. Aging Neurosci..

[40]  De-xiang Liu,et al.  Effects of curcumin on learning and memory deficits, BDNF, and ERK protein expression in rats exposed to chronic unpredictable stress , 2014, Behavioural Brain Research.

[41]  F. Carreño,et al.  Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine , 2014, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[42]  L. Hurley,et al.  Antidepressant effects of resveratrol in an animal model of depression , 2014, Behavioural Brain Research.

[43]  John H. Zhang,et al.  Curcumin inhibits microglia inflammation and confers neuroprotection in intracerebral hemorrhage. , 2014, Immunology letters.

[44]  D. Yoo,et al.  Effects of curcumin (Curcuma longa) on learning and spatial memory as well as cell proliferation and neuroblast differentiation in adult and aged mice by upregulating brain-derived neurotrophic factor and CREB signaling. , 2014, Journal of medicinal food.

[45]  Natalia Gulyaeva,et al.  Rodent Models of Depression: Neurotrophic and Neuroinflammatory Biomarkers , 2014, BioMed research international.

[46]  Jiaqing Yang,et al.  Neuroprotective effect of curcumin on hippocampal injury in 6-OHDA-induced Parkinson's disease rat. , 2014, Pathology, research and practice.

[47]  Yvette I. Sheline,et al.  An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice , 2014, Science Translational Medicine.

[48]  Michael Maes,et al.  Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. , 2014, Current pharmaceutical design.

[49]  Xuelian Ma,et al.  Effects of curcumin on chronic, unpredictable, mild, stress-induced depressive-like behaviour and structural plasticity in the lateral amygdala of rats. , 2014, The international journal of neuropsychopharmacology.

[50]  G. Nicolardi,et al.  Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses , 2014, Innate immunity.

[51]  Xueer Wang,et al.  Resveratrol prevents impaired cognition induced by chronic unpredictable mild stress in rats , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[52]  R. Duman.  Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections , 2014, Dialogues in clinical neuroscience.

[53]  Labchan Rajbhandari,et al.  Curcumin protects axons from degeneration in the setting of local neuroinflammation , 2014, Experimental Neurology.

[54]  N. Müller.  Immunology of Major Depression , 2014, Neuroimmunomodulation.

[55]  D. Charney,et al.  Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. , 2014, The international journal of neuropsychopharmacology.

[56]  F. Barale,et al.  Curcumin as a Therapeutic Agent in Dementia: A Mini Systematic Review of Human Studies , 2014, TheScientificWorldJournal.

[57]  Chun-mei Chen,et al.  Curcumin protects against ischemic spinal cord injury: The pathway effect , 2013, Neural regeneration research.

[58]  Jun Li,et al.  Antidepressant-like effect of resveratrol: Involvement of antioxidant effect and peripheral regulation on HPA axis , 2013, Pharmacology Biochemistry and Behavior.

[59]  Y. Izumi,et al.  Indistinguishable Synaptic Pharmacodynamics of the N-Methyl-d-Aspartate Receptor Channel Blockers Memantine and Ketamine , 2013, Molecular Pharmacology.

[60]  M. Pallàs,et al.  Resveratrol: new avenues for a natural compound in neuroprotection. , 2013, Current pharmaceutical design.

[61]  Woosuk Kim,et al.  Antidepressants for neuro-regeneration: from depression to Alzheimer’s disease , 2013, Archives of pharmacal research.

[62]  R. Villanueva.  Neurobiology of Major Depressive Disorder , 2013, Neural plasticity.

[63]  B. Czéh,et al.  Talking to the synapse: how antidepressants can target glial cells to reshape brain circuits. , 2013, Current drug targets.

[64]  E. Castrén.  Neuronal network plasticity and recovery from depression. , 2013, JAMA psychiatry.

[65]  F. Lotrich,et al.  Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications , 2013, Neuroscience.

[66]  Jiang Shen,et al.  Ketamine attenuates the lipopolysaccharide-induced inflammatory response in cultured N2a cells. , 2013, Molecular medicine reports.

[67]  O. Wiborg.  Chronic mild stress for modeling anhedonia , 2013, Cell and Tissue Research.

[68]  Y. Tizabi,et al.  Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR , 2013, Psychopharmacology.

[69]  M. Kock,et al.  Ketamine and Peripheral Inflammation , 2013, CNS neuroscience & therapeutics.

[70]  G. Testylier,et al.  Treatment of Status Epilepticus with Ketamine, Are we There yet? , 2013, CNS neuroscience & therapeutics.

[71]  R. Taylor,et al.  Nicotine Blocks the Depressogenic Effects of Alcohol: Implications for Drinking-Smoking Co-Morbidity , 2013, Journal of drug and alcohol research.

[72]  Inmaculada Posadas,et al.  Send Orders of Reprints at Reprints@benthamscience.net Nicotinic Receptors in Neurodegeneration , 2022 .

[73]  R. Hen,et al.  Brain-derived neurotrophic factor ( BDNF ) , depression and adult hippocampal neurogenesis , 2013 .

[74]  G. Zhai,et al.  Advances in clinical study of curcumin. , 2013, Current pharmaceutical design.

[75]  Feng Zhang,et al.  Resveratrol Protects Cortical Neurons against Microglia‐mediated Neuroinflammation , 2013, Phytotherapy research : PTR.

[76]  L. Hurley,et al.  Protective Effects of Curcumin Against Rotenone and Salsolinol-Induced Toxicity: Implications for Parkinson’s Disease , 2013, Neurotoxicity Research.

[77]  L. Hurley,et al.  Neuroinflammation, Neurodegeneration, and Depression , 2013, Neurotoxicity Research.

[78]  J. Yakel.  Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease , 2013, Pflügers Archiv - European Journal of Physiology.

[79]  B. Gorzalka,et al.  Neurobiology of chronic mild stress: Parallels to major depression , 2012, Neuroscience & Biobehavioral Reviews.

[80]  W. Geldenhuys,et al.  Curcumin and neurodegenerative diseases: a perspective , 2012, Expert opinion on investigational drugs.

[81]  Kevin Ellsworth,et al.  α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation , 2012, Journal of Neuroinflammation.

[82]  C. Metz,et al.  Nicotinic Acetylcholine Receptor Agonists Attenuate Septic Acute Kidney Injury in Mice by Suppressing Inflammation and Proteasome Activity , 2012, PloS one.

[83]  J. Segura-Aguilar,et al.  Protective Effects of Nicotine Against Aminochrome-Induced Toxicity in Substantia Nigra Derived Cells: Implications for Parkinson’s Disease , 2012, Neurotoxicity Research.

[84]  G. Testylier,et al.  Combinations of ketamine and atropine are neuroprotective and reduce neuroinflammation after a toxic status epilepticus in mice. , 2012, Toxicology and applied pharmacology.

[85]  E. Palazidou.  The neurobiology of depression. , 2012, British medical bulletin.

[86]  Nanxin Li,et al.  Signaling pathways underlying the rapid antidepressant actions of ketamine , 2012, Neuropharmacology.

[87]  Graeme Martin,et al.  Network analysis and the connectopathies: current research and future approaches. , 2012, Nonlinear dynamics, psychology, and life sciences.

[88]  M. Bharath,et al.  Curcumin: a potential neuroprotective agent in Parkinson's disease. , 2012, Current pharmaceutical design.

[89]  D. Dhawan,et al.  N-Methyl N-Nitrosourea Induced Functional and Structural Alterations in Mice Brain-Role of Curcumin , 2012, Neurotoxicity Research.

[90]  S. Hauser,et al.  Alcohol induced depressive-like behavior is associated with a reduction in hippocampal BDNF , 2011, Pharmacology Biochemistry and Behavior.

[91]  H. Kurihara,et al.  Resveratrol improves cognitive function in mice by increasing production of insulin-like growth factor-I in the hippocampus. , 2011, The Journal of nutritional biochemistry.

[92]  K. Chopra,et al.  Curcumin ameliorates reserpine-induced pain–depression dyad: Behavioural, biochemical, neurochemical and molecular evidences , 2011, Psychoneuroendocrinology.

[93]  S. Chaki,et al.  Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression , 2011, Behavioural Brain Research.

[94]  Judith A. Potashkin,et al.  The Promise of Neuroprotective Agents in Parkinson’s Disease , 2011, Front. Neur..

[95]  S. Lakhan,et al.  Anti-inflammatory effects of nicotine in obesity and ulcerative colitis , 2011, Journal of Translational Medicine.

[96]  K. Kendler,et al.  Nicotine withdrawal-induced negative affect is a function of nicotine dependence and not liability to depression or anxiety. , 2011, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[97]  E. Kavalali,et al.  NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.

[98]  Cai Song,et al.  Cytokines mediated inflammation and decreased neurogenesis in animal models of depression , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[99]  V. Yeragani,et al.  Antidepressants: From MAOIs to SSRIs and more , 2011, Indian journal of psychiatry.

[100]  R. Taylor,et al.  Toxic Effects of Low Alcohol and Nicotine Combinations in SH-SY5Y Cells are Apoptotically Mediated , 2011, Neurotoxicity Research.

[101]  Junfa Li,et al.  Inhibition of Neuron-Specific CREB Dephosphorylation is Involved in Propofol and Ketamine-Induced Neuroprotection Against Cerebral Ischemic Injuries of Mice , 2011, Neurochemical Research.

[102]  K. Ono,et al.  REVIEW: Curcumin and Alzheimer's Disease , 2010, CNS neuroscience & therapeutics.

[103]  Ming D. Li,et al.  Nicotinic Modulation of Innate Immune Pathways Via α7 Nicotinic Acetylcholine Receptor , 2010, Journal of Neuroimmune Pharmacology.

[104]  K. Manaye,et al.  Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[105]  P. Pagel,et al.  Neuroprotection by ketamine: a review of the experimental and clinical evidence. , 2010, Journal of cardiothoracic and vascular anesthesia.

[106]  M. Quik,et al.  Multiple roles for nicotine in Parkinson's disease. , 2009, Biochemical pharmacology.

[107]  Julie S. Jurenka.  Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. , 2009, Alternative medicine review : a journal of clinical therapeutic.

[108]  T. Connor,et al.  Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. , 2009, The international journal of neuropsychopharmacology.

[109]  F. Shi,et al.  Nicotine and inflammatory neurological disorders , 2009, Acta Pharmacologica Sinica.

[110]  D. Overstreet,et al.  Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-Hooded rat, an animal model of co-morbid depression and alcoholism , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[111]  J. Sheu,et al.  Inhibitory Effects of Ketamine on Lipopolysaccharide-Induced Microglial Activation , 2009, Mediators of inflammation.

[112]  J. Das,et al.  Additive Protective Effects of Donepezil and Nicotine Against Salsolinol-Induced Cytotoxicity in SH-SY5Y Cells , 2009, Neurotoxicity Research.

[113]  S. Kulkarni,et al.  Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes , 2009, Pharmacology Biochemistry and Behavior.

[114]  F. Shi,et al.  Nicotinic Attenuation of Central Nervous System Inflammation and Autoimmunity1 , 2009, The Journal of Immunology.

[115]  R. Copeland,et al.  Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity , 2007, Neurotoxicity Research.

[116]  Yasmine M. Kanaan,et al.  Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: Implications for parkinson’s disease , 2005, Neurotoxicity Research.

[117]  B. Aggarwal,et al.  Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. , 2009, The international journal of biochemistry & cell biology.

[118]  M. Maj,et al.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression , 2009, Metabolic Brain Disease.

[119]  P. Davies,et al.  Therapeutic potential of resveratrol in Alzheimer's disease , 2008, BMC Neuroscience.

[120]  A. Zangen,et al.  Age‐dependent effects of chronic stress on brain plasticity and depressive behavior , 2008, Journal of neurochemistry.

[121]  S. Kulkarni,et al.  Antidepressant activity of curcumin: involvement of serotonin and dopamine system , 2008, Psychopharmacology.

[122]  P. Gressens,et al.  Neurotrophins and cytokines in neuronal plasticity. , 2008, Novartis Foundation symposium.

[123]  E. Castrén,et al.  Neurotrophins in depression and antidepressant effects. , 2008, Novartis Foundation symposium.

[124]  F. Gage,et al.  Mechanisms and Functional Implications of Adult Neurogenesis , 2008, Cell.

[125]  Guang Chen,et al.  Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.

[126]  D. Hedeker,et al.  Nicotine effects on affective response in depression-prone smokers , 2008, Psychopharmacology.

[127]  G. Juckel,et al.  Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. , 2007, Journal of clinical psychopharmacology.

[128]  B. Aggarwal,et al.  Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). , 2007, Free radical biology & medicine.

[129]  B. Aggarwal,et al.  Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. , 2007, Carcinogenesis.

[130]  Y. Chan,et al.  Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. , 2007, CNS and Neurological Disorders - Drug Targets.

[131]  B. Czéh,et al.  What causes the hippocampal volume decrease in depression? , 2007, European Archives of Psychiatry and Clinical Neuroscience.

[132]  Wei Li,et al.  Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms. , 2007, Life sciences.

[133]  M. Thun,et al.  Temporal relationship between cigarette smoking and risk of Parkinson disease , 2007, Neurology.

[134]  R. Drucker-Colín,et al.  Long-term changes in sleep and depressive symptoms of smokers in abstinence. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[135]  B. Aggarwal,et al.  Curcumin: the Indian solid gold. , 2007, Advances in experimental medicine and biology.

[136]  B. Spring,et al.  Influence of nicotine on positive affect in anhedonic smokers , 2007, Psychopharmacology.

[137]  E. Kua,et al.  Curry consumption and cognitive function in the elderly. , 2006, American journal of epidemiology.

[138]  F. Joseph McClernon,et al.  Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial , 2006, Psychopharmacology.

[139]  J. Langston,et al.  Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates , 2006, Journal of neurochemistry.

[140]  S. Gold,et al.  Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. , 2006, Neurologic clinics.

[141]  D. Luckenbaugh,et al.  A double-blind, placebo-controlled study of memantine in the treatment of major depression. , 2006, The American journal of psychiatry.

[142]  Xue-jun Li,et al.  Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats , 2005, Pharmacology Biochemistry and Behavior.

[143]  Xue-jun Li,et al.  The effects of curcumin on depressive-like behaviors in mice. , 2005, European journal of pharmacology.

[144]  R. Drucker-Colín,et al.  Effects of transderman nicotine on mood and sleep in nonsmoking major depresssed patients , 1995, Psychopharmacology.

[145]  C. Pomerleau,et al.  Euphoriant effects of nicotine in smokers , 2005, Psychopharmacology.

[146]  R. Sapolsky.  Is impaired neurogenesis relevant to the affective symptoms of depression? , 2004, Biological Psychiatry.

[147]  T. Taniguchi,et al.  The Antiinflammatory Effects of Ketamine in Endotoxemic Rats During Moderate and Mild Hypothermia , 2004, Anesthesia and analgesia.

[148]  H. Kraemer,et al.  Untreated depression and hippocampal volume loss. , 2003, The American journal of psychiatry.

[149]  Yan Cui,et al.  EFFECTS OF KETAMINE/XYLAZINE ON EXPRESSION OF TUMOR NECROSIS FACTOR‐&agr;, INDUCIBLE NITRIC OXIDE SYNTHASE, AND CYCLO‐OXYGENASE‐2 IN RAT GASTRIC MUCOSA DURING ENDOTOXEMIA , 2003, Shock.

[150]  Yan Cui,et al.  Ketamine/xylazine attenuates LPS-induced iNOS expression in various rat tissues. , 2003, The Journal of surgical research.

[151]  H. Manji,et al.  Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression , 2003, Biological Psychiatry.

[152]  Haiyun Xu,et al.  Dose-Related Effects of Chronic Antidepressants on Neuroprotective Proteins BDNF, Bcl-2 and Cu/Zn-SOD in Rat Hippocampus , 2003, Neuropsychopharmacology.

[153]  Y. Gupta,et al.  Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. , 2002, Life sciences.

[154]  Zhirong Wang,et al.  Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. , 2002, International journal of molecular medicine.

[155]  S. Sachdeva,et al.  Prevalence of Dementia in an Urban Indian Population , 2001, International Psychogeriatrics.

[156]  T. Taniguchi,et al.  Ketamine Inhibits Endotoxin-induced Shock in Rats , 2001, Anesthesiology.

[157]  S. DeKosky,et al.  Incidence of Alzheimer’s disease in a rural community in India , 2001, Neurology.

[158]  A. Glassman,et al.  Smoking cessation and the course of major depression: a follow-up study , 2001, The Lancet.

[159]  H. Manji,et al.  Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. , 2001, Psychopharmacology bulletin.

[160]  H. Petrovitch,et al.  Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson’s Disease , 2001, Drugs & aging.

[161]  K. Fuxe,et al.  Central nicotinic receptors, neurotrophic factors and neuroprotection , 2000, Behavioural Brain Research.

[162]  D. Overstreet,et al.  Depressive Characteristics of FSL Rats Involvement of Central Nicotinic Receptors , 2000, Pharmacology Biochemistry and Behavior.

[163]  S. Hall,et al.  Development of major depression after treatment for smoking cessation. , 2000, The American journal of psychiatry.

[164]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[165]  D. Overstreet,et al.  Antidepressant Effect of Ingested Nicotine in Female Rats of Flinders Resistant and Sensitive Lines , 1999, Physiology & Behavior.

[166]  D. Overstreet,et al.  Antidepressant effects of nicotine in an animal model of depression , 1999, Psychopharmacology.

[167]  M. Miloso,et al.  Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? , 1999, Drugs under experimental and clinical research.

[168]  T. Horie,et al.  Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. , 1999, Pharmacological research.

[169]  M. Toru,et al.  Antidepressantlike Effects of Chronic Nicotine on Learned Helplessness Paradigm in Rats , 1998, Biological Psychiatry.

[170]  A. Glassman,et al.  Major depression following smoking cessation. , 1997, The American journal of psychiatry.

[171]  D. Abrams,et al.  Development of major depressive disorder during smoking-cessation treatment. , 1996, The Journal of clinical psychiatry.

[172]  J. Baron.  Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. , 1996, British Medical Bulletin.

[173]  G. Kuttan,et al.  Anti-tumour and antioxidant activity of natural curcuminoids. , 1995, Cancer letters.

[174]  P. Kroboth,et al.  Nighttime Dosing of Triazolam in Patients with Liver Disease and Normal Subjects: Kinetics and Daytime Effects , 1987, Journal of clinical pharmacology.

[175]  N. Harrison,et al.  Quantitative studies on some antagonists of N‐methyl D‐aspartate in slices of rat cerebral cortex , 1985, British journal of pharmacology.

[176]  R. Baumann,et al.  Cigarette smoking and Parkinson disease , 1980, Neurology.

[177]  O. P. Sharma.  Antioxidant activity of curcumin and related compounds. , 1976, Biochemical pharmacology.

[178]  M. Nefzger,et al.  A retrospective study of smoking in Parkinson's disease. , 1968, American journal of epidemiology.

[179]  H. Dorn.  Tobacco consumption and mortality from cancer and other diseases. , 1959, Acta - Unio Internationalis Contra Cancrum.

[180]  M. Crispin.  World Federation for Mental Health , 1958, Nature.